Drugs / VH4527079
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06652958 | Oct 2024 → Sep 2026 overdue | HIV infectious disease | ViiV Healthcare | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VH4527079 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06652958 ↗ |
| Modality | Monoclonal antibody | “Human Monoclonal Antibody” NCT06652958 ↗ |
| Route | Intravenous | “administered either by SC injection or IV infusion respectively.” NCT06652958 ↗ |
| Route | Subcutaneous | “administered either by SC injection or IV infusion respectively.” NCT06652958 ↗ |